Shanghai Henlius Biotech
Shanghai Henlius Biotech, also known as Henlius, is a prominent biopharmaceutical company headquartered in Shanghai, China. Founded in 2010, the company has rapidly established itself in the biotechnology industry, focusing on the research, development, and manufacturing of innovative monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. With a strong operational presence in both domestic and international markets, Henlius has achieved significant milestones, including the successful launch of its flagship products, which are distinguished by their high quality and affordability. The company is recognised for its commitment to advancing biopharmaceutical solutions, positioning itself as a key player in the global market. Henlius continues to expand its portfolio, aiming to enhance patient outcomes through cutting-edge therapies.
DitchCarbon Score
How does Shanghai Henlius Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Henlius Biotech's score of 29 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shanghai Henlius Biotech's reported carbon emissions
In 2023, Shanghai Henlius Biotech reported total carbon emissions of approximately 30,000,000 kg CO2e, comprising 6,908,630 kg CO2e from Scope 1, 15,064,370 kg CO2e from Scope 2, and 21,973,000 kg CO2e from Scope 3 emissions. This marked a slight increase in total emissions compared to 2022, where total emissions were about 29,000,000 kg CO2e. In 2022, the company’s emissions included 6,480,150 kg CO2e from Scope 1, 14,683,780 kg CO2e from Scope 2, and 21,163,930 kg CO2e from Scope 3. The trend indicates a growing operational footprint as revenue increased from approximately 506 million USD in 2022 to about 782 million USD in 2023. Shanghai Henlius Biotech has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. The absence of defined reduction strategies suggests a need for enhanced climate commitments in line with industry standards. The company’s emissions intensity metrics indicate a focus on improving efficiency, but further transparency regarding future climate strategies would be beneficial for stakeholders.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 3,427,130 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 6,168,490 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shanghai Henlius Biotech is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
